Adverum Biotechnologies(ADVM) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents ...